izpis_h1_title_alt

Novel scaffolds for modulation of NOD2 identified by pharmacophore-based virtual screening
ID Guzelj, Samo (Author), ID Tomašič, Tihomir (Author), ID Jakopin, Žiga (Author)

URLURL - Source URL, Visit https://www.mdpi.com/2218-273X/12/8/1054 This link opens in a new window
URLURL - Source URL, Visit https://www.mdpi.com/2218-273X/12/8/1054 This link opens in a new window
.pdfPDF - Presentation file, Download (24,71 MB)
MD5: F226A94A9A0B4F7A80AFB676134B32DA

Abstract
Nucleotide-binding oligomerization domain-containing protein 2 (NOD2) is an innate immune pattern recognition receptor responsible for the recognition of bacterial peptidoglycan fragments. Given its central role in the formation of innate and adaptive immune responses, NOD2 represents a valuable target for modulation with agonists and antagonists. A major challenge in the discovery of novel small-molecule NOD2 modulators is the lack of a co-crystallized complex with a ligand, which has limited previous progress to ligand-based design approaches and high-throughput screening campaigns. To that end, a hybrid docking and pharmacophore modeling approach was used to identify key interactions between NOD2 ligands and residues in the putative ligand-binding site. Following docking of previously reported NOD2 ligands to a homology model of human NOD2, a structure-based pharmacophore model was created and used to virtually screen a library of commercially available compounds. Two compounds, 1 and 3, identified as hits by the pharmacophore model, exhibited NOD2 antagonist activity and are the first small-molecule NOD2 modulators identified by virtual screening to date. The newly identified NOD2 antagonist scaffolds represent valuable starting points for further optimization.

Language:English
Keywords:antagonist, homology modeling, NOD2, Nucleotide-binding oligomerization, pharmacophore modeling, virtual screening
Typology:1.01 - Original Scientific Article
Organization:FFA - Faculty of Pharmacy
Publication date:01.01.2022
Year:2022
Number of pages:17 str.
Numbering:Vol. 12, iss. 8, art. 1054
PID:20.500.12556/RUL-138680-86544121-2823-7222-34ef-8017072a3c05 This link opens in a new window
UDC:615.4:54:616-006
ISSN on article:2218-273X
DOI:10.3390/biom12081054 This link opens in a new window
COBISS.SI-ID:117616387 This link opens in a new window
Publication date in RUL:09.08.2022
Views:361
Downloads:93
Metadata:XML RDF-CHPDL DC-XML DC-RDF
:
Copy citation
Share:Bookmark and Share

Record is a part of a journal

Title:Biomolecules
Shortened title:Biomolecules
Publisher:MDPI
ISSN:2218-273X
COBISS.SI-ID:519952921 This link opens in a new window

Licences

License:CC BY 4.0, Creative Commons Attribution 4.0 International
Link:http://creativecommons.org/licenses/by/4.0/
Description:This is the standard Creative Commons license that gives others maximum freedom to do what they want with the work as long as they credit the author.
Licensing start date:09.08.2022

Secondary language

Language:Slovenian
Keywords:antagonisti, modeliranje homologije, NOD2, oligomerizacija, ki veže nukleotide, modeliranje farmakoforja, virtualno rešetanje

Projects

Funder:ARRS - Slovenian Research Agency
Project number:P1-0208
Name:Farmacevtska kemija: načrtovanje, sinteza in vrednotenje učinkovin

Funder:ARRS - Slovenian Research Agency
Project number:P1-0420
Name:Napredna imunološka zdravila in celični pristopi v farmaciji

Funder:ARRS - Slovenian Research Agency
Project number:J3-9256
Name:Razvoj agonistov receptorja NOD2 ter dualnih NOD2/TLR7 agonističnih konjugatov kot novih adjuvansov za cepiva

Similar documents

Similar works from RUL:
Similar works from other Slovenian collections:

Back